1. Bilezikian JP, Khan AA and Potts Jr JT. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab. 2009 Feb; 94(2):335–339.
2. Bilezikian JP, Brandi ML, Eastell R, Silverberg S, Udelsman R, Marcocci C and Potts Jr JT. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. J Clin Endocrinol Metab. Oct;99(10):3561-9.doi: 10.1210/jc.2014-1413.
3. American Society for Bone and Mineral Research. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. / editor-in-chief, Clifford J. Rosen ; Ames, Iowa: Wiley-Blackwell, 201.
4. Handbook of parathyroid diseases – A case-based practical guide. Editors AA Khan and OH Clark, Springer 2012, DOI 10,1007/978-1-4614-2164-1.
5. Алгоритмы обследования и лечения пациентов в эндокринологии. Часть II. Гиперпаратиреоз. Методические рекомендации. Под редакцией академика РАН и РАМН Дедова И.И. и член-корреспондента РАМН Мельниченко Г.А. М.; 2009 г.
6. Yu N, Donnan PT, Murphy MJ and Leese P. Epidemiology of primary hyperparathyroidism in tayside, Scotland, UK. Clinical Endocrinology. 2009; 71:485-493.
7. Wermers R, Khosla S, Atkinson EJ et al. Incidence of primary hyperparathyroidism in rochester, minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006; Jan;21(1):171 – 7.
8. Wermers R, Khosla S, Atkinson E, Hodgson S, O'Fallon W , Melton,LJ,III. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997; 126: 433-440.
9. AACE/AAES position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005; 11:49-54.
10. Chiavistelli S, Bilezikian J. Does calcium intake influence the development of primary hyperparathyroidism. IBMS BoneKEy. 2013; 10:314.
11. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122–1129.
12. De Lucia F, Minisola S, Romagnoli E, et al. Effect of gender and geographic location on the expression of primary hyperparathyroidism. J Endocrinol Invest. 2013;36:123-126.
13. Мокрышева Н.Г. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения. - Дисс. ...докт.мед.наук - М.-2011.-С.253.
14. Мокрышева Н.Г., Рожинская Л.Я., Перетокина Е.В., Ростомян Л.Г., Мирная С.С., Пронин В.С., Маркина Н.В., Шебешева Е.Н., Анциферов М.Б., Дедов И.И. Анализ основных эпидемиологических характеристик первичного гиперпаратиреоза в России ( по данным регистра). Проблемы эндокринологии. 2012. Т. 58. № 5. С. 16-20.
15. Silverberg SJ, Walker MD and Bilezikian JP. Asymptomatic Primary Hyperparathyroidism. J Clin Densitom. 2013; 16(1): 14-21.
16. Acute hypercalcaemia; Society for Endocrinology, 2013
17. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Jian-Min L, Minisola S, Rejnmark L, Silva BC, Walker MD and Bilezikian JP. Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. Oct;99(10):3561-9. doi: 10.1210/jc.2014-1413.
18. Bilezikian JP, Potts JT Jr, Fuleihan G-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res. 2002;17(Suppl 2):N2-N11.
19. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery [erratum in N Engl J Med. 2000;342:144]. N Engl J Med. 1999;341:1249-1255.
20. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27:216-222.
21. Вороненко И.В. Состояние сердечно-сосудистой системы у женщин с первичным гиперпаратиреозом и динамика выявленных нарушений при лечении основного заболевания. – Дисс.канд.мед.наук. – М. – 2009.-С.114.
22. Richards ML, Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? Surgery. 1999;126:1160-1166.
23. Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003; 26:1136-1142.
24. Priya G, Jyostna VP, Chamber S, Bal CS et al. Clinical and laboratory profil of primary hyperparathyroidism in India. Postgrad Med J 2008; 84:34-39.
25. Gao P, D’Amour P. Evolution of the parathyroid hormone (PTH) assays. Importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab. 2005;51:21-9.
26. Cole DE, Webb S, Chan PC. Update on parathyroid hormone: new tests and new challenges for external quality assessment. Clin Biochem. 2007;40:585–590.
27. Souberbielle JP, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77:93-100.
28. Cavalier E, Plebani M, Delanaye P, Souberbielle JC. Considerations in parathyroid hormone testing. Clin Chem Lab Med. 2015 Nov;53(12):1913-9. doi: 10.1515/cclm-2015-0314.
29. Boudou P1, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab. 2005 Dec;90(12):6370-2.
30. "A Practical Approach to Hypercalcemia - May 1, 2003 - American Family Physician". Retrieved 2009-03-29.
31. Rolighed L1, Bollerslev J, Mosekilde L. Vitamin D treatment in primary hyperparathyroidism. Curr Drug Saf. 2011 Apr;6(2):100-7.
32. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ДЕФИЦИТ ВИТАМИНА D У ВЗРОСЛЫХ: ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА, Москва 2015.
33. Saliba W, Barnett O, Rennert HS, Lavi I, Rennert G. The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels. Am J Med. 2011 Dec. 124(12):1165-70.